Oncology and Hematology News and Journal Articles
The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.
Advocacy is about making sure that our lawmakers enact the best healthcare policies for our patients. Just as we have a duty to our patients in the clinic, we also have a duty to advocate for laws that benefit patients’ health.
Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.
The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.
Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.
A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer.
In this video from the 2015 ONS meeting, Dr. Sipples talks about effective management of side effects for patients taking afatinib, an oral, targeted agent for lung cancer.
In this video from the 2015 ONS meeting, Dr. Gwyn talks about nurse practitioners delivering bad news to patients by utilizing the SPIKES protocol.
In this video from the 2015 ONS meeting, Dr. Omran discusses the high-risk of colorectal cancer among the Jordanian population and the need to promote more screening awareness.
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.